Amrish Malhi, MD
Interventional Cardiology · Indianapolis, INNPI 1033395330
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 48.8% of the total. Reporting peaked in 2022 at $12,550 and has fallen 80.3% since, to $2,467 in 2025.
Across 370 payments — averaging $100.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$18K
- Abbott$6K
- Boston Scientific$5K
- Penumbra, Inc.$2K
- Heartflow, Inc.$818
- Abiomed$783
- plus $5K from 30 others
What the payments were for
- Consulting fees$15,00040%
- Travel & lodging$6,49217%
- Food & beverage$15,73442%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 26 | $18,197 |
| Abbott | 73 | $5,551 |
| Boston Scientific | 48 | $4,514 |
| Penumbra, Inc. | 7 | $2,284 |
| Heartflow, Inc. | 10 | $818 |
| Abiomed | 11 | $783 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 42 | $715 |
| Shockwave Medical, Inc | 4 | $570 |
| AstraZeneca | 9 | $372 |
| Johnson & Johnson | 19 | $366 |
| Novartis | 32 | $360 |
| Philips North America LLC | 4 | $348 |
| Medtronic | 12 | $272 |
| Pfizer | 8 | $240 |
| Merck | 11 | $225 |
| Amgen | 11 | $202 |
| W. L. Gore & Associates, Inc. | 1 | $193 |
| Cvrx, Inc. | 2 | $162 |
| Edwards Lifesciences | 1 | $148 |
| E.r. Squibb & Sons, L.L.C. | 8 | $142 |
| Biotronik Inc. | 1 | $139 |
| Boehringer Ingelheim | 5 | $123 |
| Lantheus Medical Imaging, Inc. | 6 | $122 |
| Cleerly, Inc. | 1 | $55 |
| Stryker | 1 | $55 |
| Chiesi USA, Inc. | 3 | $51 |
| Cardiovascular Systems Inc. | 2 | $48 |
| Teleflex LLC | 2 | $40 |
| Lexicon Pharmaceuticals, Inc. | 2 | $39 |
| Baxter Healthcare | 1 | $34 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $33 |
| Impulse Dynamics (USA) Inc. | 1 | $32 |
| Imperative Care, Inc | 1 | $30 |
| Argon Medical Devices, Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Artis icono floor$2,746
- Indigo System$2,228
- EKOSONIC$2,211
- JOT DX$826
- FFRct$556
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$551
- Impella$537
- GENERAL VASCULAR ACCESS$533
- OPTIS$473
- Confirm Rx$414
- XIENCE SIERRA$296
- IGT Devices Und$284
- AMPLATZER AMULET$280
- AVEIR$275
- COROFLOW$257
- MitraClip$254
- Xience Sierra Coronary Stent$208
- VIABAHN Endoprosthesis$193
- Quadra Assura CRT Defibrillator$168
- LINQ II$165
How this compares
$37,326 in reported general payments places this provider in the 85th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 162 | $172,349 |
| EntrestoSacubitril/Valsartan | 49 | $63,337 |
| XareltoRivaroxaban | 23 | $27,287 |
| FarxigaDapagliflozin Propanediol | 16 | $16,655 |
| BrilintaTicagrelor | 21 | $15,705 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $3,168 |
| Metoprolol Succinate | 204 | $2,238 |
| Atorvastatin Calcium | 239 | $1,634 |
| Ezetimibe | 31 | $1,113 |
| ClopidogrelClopidogrel Bisulfate | 92 | $1,104 |
| Carvedilol | 101 | $739 |
| Potassium Chloride | 51 | $726 |
| Losartan Potassium | 87 | $576 |
| Amiodarone Hcl | 50 | $540 |
| Amlodipine Besylate | 123 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $240 | $172,349162 claims |
| NovartisEntresto | $360 | $63,33749 claims |
| AstraZenecaFarxiga, Brilinta | $372 | $32,36037 claims |
| Johnson & JohnsonXarelto | $366 | $27,28723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Indianapolis
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Michael BallIndianapolis$76K
- Anjan SinhaIndianapolis$54K
- Nitesh GadeelaIndianapolis$48K
- George RevtyakIndianapolis$45K
- Scott SharpIndianapolis$41K
- Jeffrey BreallIndianapolis$21K
- Sandeep DubeIndianapolis$21K
- Kevin BallIndianapolis$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.